Drug Profile
Collagen type V oral solution
Alternative Names: IW001Latest Information Update: 14 Jan 2022
Price :
$50
*
At a glance
- Originator ImmuneWorks
- Developer ImmuneWorks; Lung Biotechnology
- Class Collagens
- Mechanism of Action T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis; Lung transplant rejection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis in USA (PO, Liquid)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-transplant-rejection in USA (PO, Liquid)
- 03 Apr 2012 ImmuneWorks & Lung Rx complete enrolment in their phase I trial for Idiopathic pulmonary fibrosis in USA (NCT01199887)